Intelligent Digital Tools for Screening of Brain Connectivity and Dementia Risk Estimation in People Affected by Mild Cognitive Impairment

NCT05159661 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-04-02

No results posted yet for this study

Summary

Every three seconds someone in the world develops dementia. There are over 50 million people worldwide living with dementia and by 2030 this figure is expected to reach 82 million. Besides time-consuming patient investigations with low discriminative power for dementia risk, current treatment options focus on late symptom management. By screening brain connectivity and dementia risk estimation in people affected by mild cognitive impairment, the European Union (EU) funded AI-Mind project will open the door to extending the 'dementia-free' period by offering proper diagnosis and early intervention. AI-Mind will develop two artificial intelligence-based digital tools that will identify dysfunctional brain networks and assess dementia risk. Personalised patient reports will be generated, potentially opening new windows for intervention possibilities.

Conditions

Sponsors & Collaborators

  • Aalto University

    collaborator OTHER
  • Accelopment AG

    collaborator OTHER
  • Alzheimer Europe

    collaborator OTHER
  • BrainSymph AS

    collaborator UNKNOWN
  • Det Norske Veritas

    collaborator UNKNOWN
  • Helsinki University Central Hospital

    collaborator OTHER
  • IRCCS San Raffaele Roma

    collaborator OTHER
  • Lurtis Rules S.L.

    collaborator UNKNOWN
  • Neuroconnect Srl

    collaborator UNKNOWN
  • Oslo Metropolitan University

    collaborator OTHER
  • Radboud University Medical Center

    collaborator OTHER
  • Tallinna Ülikool

    collaborator UNKNOWN
  • Universidad Complutense de Madrid

    collaborator OTHER
  • Catholic University of the Sacred Heart

    collaborator OTHER
  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Ira Haraldsen, PhD, MD · Oslo University Hospital

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2025-09-30
Completion
2026-02-27

Countries

  • Finland
  • Italy
  • Norway
  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159661 on ClinicalTrials.gov